Edwards CM, Todd JF, Mahmoudi M, Wang Z, Wang RM, Ghatei MA, et al
#Pharma #GLP1 #ObesityTreatment #DrugDevelopment #HealthcareInnovation #EliLilly #NovoNordisk #PharmaceuticalIndustry To view or add a comment, sign in NEW DRUG APPROVAL ALERT The FDA has approved Foundayo (orforglipron), a new once-daily oral GLP-1 for chronic weight management in adults with obesity, or adults with overweight plus at least one weight-related condition
Cycle Length: Minimum 24 weeks
Why Side Effects Are Usually Worse at the Beginning The dose escalation schedule used with GLP-1 medications is specifically designed to reduce side effect burden by allowing the body time to adapt before the dose increases
Will GLP-1 ever be affordable
Semaglutide has been on the market longer and has more extensive clinical experience and usage history